I

ImmVirX

16 employees

ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.

Basic info

Industry

biotechnology research

Sectors

Health Diagnostics
Health Care
colorectal cancer
immuno-oncology
oncology
biotech

Date founded

2019

Funding rounds raised

Total raised

$25M

from 3 investors over 3 rounds

I

ImmVirX raised $25M on June 5, 2023

Investors: Acorn Capital Ltd and OneVentures

I

ImmVirX raised $22M on May 14, 2021

Investors: Acorn Capital Ltd

FAQ